India to Dominican Republic: Acetaminophen Export Trade Route

To import Acetaminophen formulations, the following approvals and registrations are mandatory:

1. Sanitary Registration (Registro Sanitario): Each pharmaceutical product must obtain a Sanitary Registration from DIGEMAPS before importation. This registration is valid for five years and is essential for legal distribution within the country.

2. Import License: An import license is required for pharmaceutical products. Importers must apply for this permit through the Department of Drugs and Pharmacies of SESPAS.

4. Dossier Format: While the Common Technical Document (CTD) format is widely accepted internationally, specific requirements for the Dominican Republic should be confirmed directly with DIGEMAPS to ensure compliance.

5. Approval Timelines: The approval process for Sanitary Registration typically ranges from 60 to 90 days from the date of application submission.

6. Product Registration Fees: Fees for Sanitary Registration and import licenses are subject to change. Importers should consult DIGEMAPS for the most current fee structure.

7. GMP Inspection Requirements: Manufacturing facilities, including those in India, must provide evidence of Good Manufacturing Practice (GMP) compliance. While on-site inspections by Dominican authorities are not always mandatory, DIGEMAPS may require GMP certificates issued by recognized authorities in the manufacturing country.

Indian exporters of Acetaminophen formulations must adhere to the following quality and GMP standards:

1. GMP Certification: Manufacturers must hold valid GMP certificates issued by recognized authorities, such as the Central Drugs Standard Control Organization (CDSCO) in India. These certificates should demonstrate compliance with international GMP standards.

2. Approved Facilities: A list of Indian manufacturing facilities approved by DIGEMAPS is not publicly disclosed. Exporters should ensure their facilities meet all regulatory requirements and maintain open communication with Dominican importers to confirm acceptance.

3. Recent Inspections and Regulatory Actions: As of March 2026, there have been no publicly reported inspections or regulatory actions by DIGEMAPS against Indian pharmaceutical companies. However, exporters should remain vigilant and ensure continuous compliance with all applicable regulations.

In the past 18 months, the following regulatory developments have occurred:

1. Adoption of Technical Regulation on Cosmetic, Personal Hygiene, and Household Products: On September 8, 2025, DIGEMAPS adopted Resolution No. 0017-2025, establishing a legal framework for the marketing, registration, and labeling of cosmetic, personal hygiene, and household products. While this regulation primarily targets non-pharmaceutical products, it underscores the Dominican Republic's commitment to stringent regulatory controls.

2. Import Licensing Procedures Notification: On October 13, 2025, the Dominican Republic submitted a notification to the World Trade Organization outlining its import licensing procedures for pharmaceuticals and sanitary products. This notification emphasizes the requirement for import permits issued by DIGEMAPS and adherence to established procedures for all pharmaceutical imports.

These developments highlight the Dominican Republic's ongoing efforts to enhance regulatory oversight and ensure the safety and efficacy of imported pharmaceutical products.

In 2025, the over-the-counter (OTC) pharmaceuticals market in the Dominican Republic is projected to generate revenue of approximately $475.34 million, with analgesics accounting for $121.20 million. This segment is expected to grow annually by 7.41% from 2025 to 2029. Acetaminophen, a widely used analgesic, is anticipated to maintain its popularity due to its effectiveness in pain relief.

The demand for acetaminophen formulations is driven by factors such as increasing health awareness, a rise in chronic pain conditions, and a growing preference for over-the-counter pain relief solutions. While specific data on domestic production versus imports of acetaminophen formulations is limited, the Dominican Republic imports a significant portion of its pharmaceutical products, including acetaminophen formulations, to meet domestic demand.

The Dominican Republic applies a 0% MFN import duty rate on pharmaceutical products classified under HS code 30049069, which includes finished acetaminophen formulations. Additionally, the country imposes an 18% Impuesto de Transferencia a los Bienes Industrializados y Servicios (ITBIS), equivalent to a value-added tax (VAT), on most goods and services. However, pharmaceutical products are generally exempt from this tax.

The Dominican Republic-Central America Free Trade Agreement (DR-CAFTA) provides preferential tariff treatment for member countries, including the United States. However, there is no free trade agreement between India and the Dominican Republic that affects pharmaceutical tariffs. There are no known anti-dumping duties specifically targeting acetaminophen formulations imported from India.

In 2024, the Dominican Republic imported pharmaceutical products worth $159.39 million from the United States, indicating a significant reliance on U.S. suppliers. While specific data on other major countries supplying acetaminophen formulations to the Dominican Republic is limited, the United States appears to be a key supplier.

India's exports of finished acetaminophen formulations to the Dominican Republic amounted to $0.2 million, representing 0.1% of India's total acetaminophen formulation exports of $232.0 million. This suggests that India's share of the Dominican Republic's total acetaminophen imports is relatively small.

Pricing data indicates that the average import price for acetaminophen formulations under HS code 30049099 in the Dominican Republic was $0.10 per unit. While specific comparative pricing data between Indian, Chinese, and European manufacturers is not readily available, India's competitive pricing and manufacturing capabilities position it as a potential key player in the Dominican Republic's acetaminophen market.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 60% of the global production volume of solid oral dosage forms, including tablets and capsules. This extensive manufacturing capacity enables India to supply a significant portion of the world's demand for acetaminophen formulations.

The country's cost structure offers substantial advantages. Establishing a U.S. FDA-compliant manufacturing facility in India requires nearly 50% less capital investment and incurs 40–70% lower operating costs compared to developed markets. These efficiencies allow Indian manufacturers to produce high-quality acetaminophen formulations at competitive prices.

India's pharmaceutical industry boasts a robust regulatory framework, with the highest number of U.S. FDA-approved manufacturing sites outside the United States. As of April 2024, 748 Indian sites (including both bulk drug and formulation facilities) were registered with the U.S. FDA. This extensive network of WHO-GMP and FDA-approved facilities ensures that Indian-produced acetaminophen formulations meet stringent international quality standards.

When comparing acetaminophen formulation exports, India offers a compelling balance of cost and quality. While specific price per unit data for finished dosage forms is proprietary, India's lower capital and operating costs translate into more affordable products without compromising quality. The country's adherence to international regulatory standards, evidenced by numerous FDA-approved facilities, ensures high-quality formulations.

China, another major producer of generic pharmaceuticals, has rapidly expanded its manufacturing capacity. In 2024, China surpassed India in new API Drug Master File (DMF) filings, indicating significant growth. However, concerns about regulatory compliance and quality control persist, making some buyers cautious.

The European Union (EU) is known for producing branded generics with a strong emphasis on quality. However, higher production costs in the EU often result in more expensive acetaminophen formulations compared to those from India.

In the Dominican Republic, local manufacturers produce acetaminophen formulations, but they may lack the scale and cost efficiencies of Indian producers. Additionally, Indian formulations are widely accepted by Dominican regulatory authorities, given their compliance with international standards.

India's pharmaceutical industry demonstrates a strong track record of supply reliability for acetaminophen formulations. The country's extensive manufacturing capacity, particularly in solid oral dosage forms, ensures consistent production. For instance, Granules India, a leading manufacturer, operates multiple facilities dedicated to producing acetaminophen formulations.

Packaging and cold chain capabilities in India are well-developed, supporting the export of various pharmaceutical products, including acetaminophen formulations. While specific data on recent supply disruptions is limited, the industry's adherence to Good Manufacturing Practices (GMP) and regular inspections by international regulatory bodies contribute to a reliable supply chain.

Top Indian manufacturers continue to expand their capacities. For example, Akums Drugs and Pharmaceuticals acquired a new facility in Baddi in December 2023 to augment tablet output. Such expansions indicate a commitment to meeting growing global demand for acetaminophen formulations.

For Dominican Republic buyers sourcing acetaminophen formulations from India, consider the following strategies:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of acetaminophen formulations.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among suppliers. Establish clear communication with potential suppliers to understand their specific requirements and negotiate terms that align with your procurement needs.

• Payment Terms: Common payment terms in India-Dominican Republic pharmaceutical trade include Letters of Credit (LC) and advance payments. Ensure that agreed-upon terms are documented to avoid misunderstandings.

• Supplier Qualification Process: Implement a thorough qualification process, including:
• Reviewing regulatory approvals (e.g., U.S. FDA, WHO-GMP certifications).
• Conducting on-site audits or virtual assessments of manufacturing facilities.
• Evaluating the supplier's track record for quality and timely delivery.

• Regulatory Compliance: Ensure that the selected suppliers comply with both Indian and Dominican Republic regulatory requirements for acetaminophen formulations.

By adopting these strategies, buyers can establish a reliable and cost-effective supply chain for acetaminophen formulations from India.

1. Verify Sanitary Registration with DIGEMAPS: Confirm that the Acetaminophen formulation is registered with the General Directorate of Medicines, Food, and Health Products (DIGEMAPS) under the Ministry of Public Health. This registration is mandatory for all pharmaceutical products imported into the Dominican Republic and is valid for five years.

2. Assess Manufacturer's GMP Certification: Ensure the Indian manufacturer holds a valid Good Manufacturing Practice (GMP) certificate recognized by the Dominican Republic authorities. This certification attests to the manufacturer's adherence to quality standards in production processes.

3. Review Drug Master File (DMF): Obtain and evaluate the DMF for the Acetaminophen formulation. The DMF provides comprehensive information on the manufacturing process, quality control, and stability data, essential for assessing product quality.

4. Confirm Product Labeling Compliance: Verify that the product labeling meets Dominican Republic regulations, including accurate product name, manufacturer details, formula, registration number, and appropriate usage instructions.

5. Evaluate Quality Management Systems: Assess the manufacturer's quality management systems to ensure they align with international standards, ensuring consistent product quality and safety.

6. Check for Regulatory Approvals in Other Markets: Determine if the manufacturer has obtained approvals from other stringent regulatory authorities, such as the U.S. FDA or the European Medicines Agency (EMA), indicating a commitment to high-quality standards.

7. Conduct a Risk Assessment: Perform a comprehensive risk assessment of the supplier, considering factors such as compliance history, financial stability, and market reputation.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for a specific batch, confirming the product meets predefined specifications.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for verifying the authenticity and origin of the product.

3. GMP Certificate: Issued by a recognized regulatory authority, this certificate confirms that the manufacturing facility complies with Good Manufacturing Practices.

4. Stability Data: Includes studies conducted under various environmental conditions to demonstrate the product's shelf life and storage requirements, ensuring efficacy throughout its intended lifespan.

5. Batch Manufacturing Records: Detailed documentation of the production process for each batch, ensuring traceability and consistency in manufacturing.

6. Drug Master File (DMF): Comprehensive document detailing the manufacturing process, quality control procedures, and other critical information about the drug product.

7. Free Sale Certificate from CDSCO: Issued by the Central Drugs Standard Control Organization (CDSCO) in India, this certificate indicates that the product is approved for sale in India and is freely sold in the domestic market.

8. Insurance Certificates: Proof of product liability insurance, providing coverage in case of product defects or adverse events.

1. Recent Regulatory Actions: Be cautious of manufacturers who have received warning letters or sanctions from regulatory bodies such as the U.S. FDA or WHO, indicating compliance issues.

2. Unusually Low Pricing: Prices significantly below market rates may suggest compromised quality or substandard manufacturing practices.

3. Lack of Stability Data: Inability to provide comprehensive stability data raises concerns about the product's shelf life and efficacy.

4. Limited Export History: Suppliers with no track record of exporting to regulated markets may lack experience in meeting stringent quality and regulatory standards.

5. Resistance to Audits: Suppliers unwilling to allow facility audits may be attempting to conceal compliance or quality issues.

1. Pre-Audit Desktop Review: Conduct a thorough review of the supplier's documentation, including licenses, certifications, and quality management systems, to identify potential issues before the on-site audit.

3. Post-Audit Corrective Actions: Document any deficiencies found during the audit and require the supplier to implement corrective actions within a specified timeframe.

4. Annual Re-Qualification Process: Establish a schedule for regular re-evaluation of the supplier to ensure ongoing compliance with quality and regulatory standards.

5. Remote Monitoring Options: Utilize technology for continuous monitoring of the supplier's quality metrics, such as periodic virtual audits and review of quality reports.

6. Audit Costs and Timelines: Budget for audit expenses, including travel and auditor fees, and plan for a timeline that includes pre-audit preparation, on-site inspection, and post-audit follow-up, typically spanning several weeks.

By meticulously following these guidelines, Dominican Republic companies can establish reliable partnerships with Indian suppliers, ensuring the consistent quality and safety of Acetaminophen formulations imported into the market.